| Diabetes Mellitus, Non-Insulin-Dependent
Jentadueto vs Segluromet
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jentadueto vs Segluromet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSegluromet has a higher rate of injection site reactions vs Jentadueto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Segluromet but not Jentadueto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jentadueto
Segluromet
At A Glance
Oral
Twice daily
DPP-4 inhibitor / biguanide
Oral
Twice daily
SGLT2 inhibitor/biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Individualized dosing orally twice daily with meals; starting at 2.5 mg linagliptin/500 mg metformin HCl twice daily for metformin-naive patients, maximum 2.5 mg linagliptin/1,000 mg metformin HCl twice daily; contraindicated if eGFR <30 mL/min/1.73 m2; initiation not recommended if eGFR 30-45 mL/min/1.73 m2.
Diabetes Mellitus, Non-Insulin-Dependent Individualize starting dosage; take orally twice daily with meals; maximum recommended dosage is 7.5 mg ertugliflozin/1,000 mg metformin HCl per dose (15 mg/2,000 mg daily); not recommended if eGFR <45 mL/min/1.73 m2; contraindicated if eGFR <30 mL/min/1.73 m2, ESRD, or dialysis.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to linagliptin, metformin, or any excipient in JENTADUETO
- Hypersensitivity to ertugliflozin, metformin, or any excipient in SEGLUROMET
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end stage-renal disease (ESRD), or dialysis
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
Adverse Reactions
Most common (>=5%) Nasopharyngitis, diarrhea (combination); diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (metformin initiation)
Serious Lactic acidosis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, rash, cholestatic/hepatocellular/mixed liver injury
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Most common (>=5%, metformin) Diarrhea, nausea, vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia, Fournier's Gangrene, vitamin B12 deficiency
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), angioedema, rash (ertugliflozin); cholestatic, hepatocellular, and mixed hepatocellular liver injury (metformin)
Pharmacology
Linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin release and reducing glucagon secretion; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Ertugliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption and lowers the renal threshold for glucose, increasing urinary glucose excretion; metformin HCl is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jentadueto
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
Segluromet
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Jentadueto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Segluromet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (1/8)
Humana
Jentadueto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Segluromet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jentadueto.
No savings programs available for Segluromet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JentaduetoView full Jentadueto profile
SeglurometView full Segluromet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.